| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1051 | 2019 |
| Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial P Caraceni, O Riggio, P Angeli, C Alessandria, S Neri, FG Foschi, ... The Lancet 391 (10138), 2417-2429, 2018 | 450 | 2018 |
| Dietary antioxidant compounds and liver health P Vitaglione, F Morisco, N Caporaso, V Fogliano Critical reviews in food science and nutrition 44 (7-8), 575-586, 2004 | 416 | 2004 |
| AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions A Lonardo, F Nascimbeni, G Targher, M Bernardi, F Bonino, E Bugianesi, ... Digestive and Liver Disease 49 (5), 471-483, 2017 | 310 | 2017 |
| International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways HJ Cordell, Y Han, GF Mells, Y Li, GM Hirschfield, CS Greene, G Xie, ... Nature communications 6 (1), 8019, 2015 | 301 | 2015 |
| Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins P Vitaglione, F Morisco, G Mazzone, DC Amoruso, MT Ribecco, ... Hepatology 52 (5), 1652-1661, 2010 | 269 | 2010 |
| F. 2005. Apple polyphenol extracts prevent damage to human gastric epithelial cells in vitro and to rat gastric mucosa in vivo G Graziani, G D’Argenio, C Tuccillo, C Loguercio, AM Ritieni Gut 54, 193-200, 0 | 244* | |
| Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects C Loguercio, V De Girolamo, I de Sio, C Tuccillo, A Ascione, F Baldi, ... Journal of hepatology 35 (5), 568-574, 2001 | 221 | 2001 |
| Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study A Vitale, P Burra, AC Frigo, F Trevisani, F Farinati, G Spolverato, M Volk, ... Journal of hepatology 62 (3), 617-624, 2015 | 219 | 2015 |
| Long-term outcome of interferon-α-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment C Carella, G Mazziotti, F Morisco, G Manganella, M Rotondi, C Tuccillo, ... The Journal of Clinical Endocrinology & Metabolism 86 (5), 1925-1929, 2001 | 182 | 2001 |
| Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between … BD Juran, GM Hirschfield, P Invernizzi, EJ Atkinson, Y Li, G Xie, R Kosoy, ... Human molecular genetics 21 (23), 5209-5221, 2012 | 172 | 2012 |
| Moderate coffee consumption increases plasma glutathione but not homocysteine in healthy subjects F Esposito, F Morisco, V Verde, A Ritieni, A Alezio, N Caporaso, ... Alimentary pharmacology & therapeutics 17 (4), 595-601, 2003 | 139 | 2003 |
| Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma A Cucchetti, F Trevisani, A Pecorelli, V Erroi, F Farinati, F Ciccarese, ... Journal of Hepatology 61 (2), 333-341, 2014 | 133 | 2014 |
| Development and validation of a new prognostic system for patients with hepatocellular carcinoma F Farinati, A Vitale, G Spolverato, TM Pawlik, T Huo, YH Lee, AC Frigo, ... PLoS medicine 13 (4), e1002006, 2016 | 131 | 2016 |
| Serum insulin‐like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus‐related … G Mazziotti, F Sorvillo, F Morisco, A Carbone, M Rotondi, G Stornaiuolo, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2002 | 128 | 2002 |
| Use of N, N-dimethyl-p-phenylenediamine to evaluate the oxidative status of human plasma V Verde, V Fogliano, A Ritieni, G Maiani, F Morisco, N Caporaso Free Radical Research 36 (8), 869-873, 2002 | 110 | 2002 |
| The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but … C Carella, G Mazziotti, F Morisco, M Rotondi, M Cioffi, C Tuccillo, ... European Journal of Endocrinology 146 (6), 743-749, 2002 | 107 | 2002 |
| Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice EG Giannini, L Bucci, F Garuti, M Brunacci, B Lenzi, M Valente, E Caturelli, ... Hepatology 67 (5), 1784-1796, 2018 | 106 | 2018 |
| Sustained virological response: a milestone in the treatment of chronic hepatitis C F Morisco, R Granata, T Stroffolini, M Guarino, L Donnarumma, L Gaeta, ... World journal of gastroenterology: WJG 19 (18), 2793, 2013 | 100 | 2013 |
| Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ... Liver international 37 (4), 514-528, 2017 | 99 | 2017 |
nicola caporasoProfessore Ordinario di Gastroenterologia - Università di Napoli Federico IIBestätigte E-Mail-Adresse bei unina.it
